Comparative assessment of humoral immune responses of aluminum hydroxide and oil-emulsion adjuvants in Influenza (H9N2) and Newcastle inactive vaccines to chickens

References

• Alexander DJ. 2001. Gordon Memorial Lecture. Newcastle disease. Br Poult Sci. 42:5–22.
   PubMed Web of Science ®Google Scholar
• Arous JB, Deville S, Pal J, Baksi S, Bertrand F, Dupuis L. 2013. Reduction of Newcastle disease vaccine dose using a novel adjuvant for cellular immune response in poultry. Proc Vaccinol. 7:28–33.
   Google Scholar
• Arthanari S, Mani G, Peng MM, Jang HT. 2014. Chitosan-HPMC-blended microspheres as a vaccine carrier for the delivery of tetanus toxoid. Artif Cells Nanomed Biotechnol. [Epub ahead of print]. DOI: 10.3109/21691401.2014.966193.
   Web of Science ®Google Scholar
• Atmar RL, Keitel WA. 2009. Adjuvants for pandemic influenza vaccines. In: Compans RW, Orenstein WA, Eds. Vaccines for Pandemic Influenza, vol. 333. Heidelberg: Springer, pp. 323–344.
   Google Scholar
• Bowersock TL, Martin S. 1999. Vaccine delivery to animals. Adv Drug Deliv Rev. 38:167–194.
   PubMed Web of Science ®Google Scholar
• Box PG, Furminger IG. 1975. Newcastle disease antibody levels in chickens after vaccination with oil emulsion adjuvant killed vaccine. Vet Rec. 96:108–111.
   PubMed Web of Science ®Google Scholar
• Brito LA, O’Hagan DT. 2014. Designing and building the next generation of improved vaccine adjuvants. J Control Release. 190:563–579.
   PubMed Web of Science ®Google Scholar
• Brugh M, Beard CW, Stone HD. 1979. Immunization of chickens and turkeys against avian influenza with monovalent and polyvalent oil emulsion vaccines. Am J Vet Res. 40:165–169.
   PubMed Web of Science ®Google Scholar
• Chauhan N, Narang J, Pundir S, Singh S, Pundir CS. 2013. Laboratory diagnosis of swine flu: a review. Artif Cells Nanomed Biotechnol. 41:189–195.
   PubMed Web of Science ®Google Scholar
• Glenny A, Pope C, Waddington H, Wallace U. 1926. Immunological notes. XVII–XXIV. J Pathol Bacteriol. 29:31–40.
   Google Scholar
• Gupta RK, Rost BE. 2000. Aluminum compounds as vaccine adjuvants. In: O'Hagan DT, Ed. Vaccine Adjuvants, vol. 42. New York: Springer, pp. 65–89.
   Google Scholar
• Gupta RK, Rost BE, Relyveld E, Siber GR. 1995. Adjuvant properties of aluminum and calcium compounds. In: Powell MF, Newman MJ, Eds. Vaccine Design, vol. 6. New York: Springer US, pp. 229–248.
   Google Scholar
• Harrison W. 1935. Some observations on the use of alum precipitated diphtheria toxoid. Am J Public Health Nations Health. 25:298–300.
   PubMedGoogle Scholar
• Herbert W. 1967. Some investigations into the mode of action of the water-in mineral-oil emulsion antigen adjuvants. Proc Int Symp Adjuvants Immun. 6:213–220.
   Google Scholar
• Kallon S, Li X, Ji J, Chen C, Xi Q, Chang S, et al. 2013. Astragalus polysaccharide enhances immunity and inhibits H9N2 avian influenza virus in vitro and in vivo. J Anim Sci Biotechnol. 4:22.
   PubMed Web of Science ®Google Scholar
• Kazemi T, Younesi V, Jadidi-Niaragh F, Yousefi M. 2015. Immunotherapeutic approaches for cancer therapy: an updated review. Artif Cells Nanomed Biotechnol. [Epub ahead of print]. DOI: 10.3109/21691401.2015.1019669.
   PubMed Web of Science ®Google Scholar
• Larghi OP, Nebel A. 1980. Rabies virus inactivation by binary ethylenimine: new method for inactivated vaccine production. J Clin Microbiol. 11:120–122.
   PubMed Web of Science ®Google Scholar
• Lee DH, Kwon JS, Lee HJ, Lee YN, Hur W, Hong YH, et al. 2011. Inactivated H9N2 avian influenza virus vaccine with gel-primed and mineral oil-boosted regimen could produce improved immune response in broiler breeders. Poult Sci. 90:1020–1022.
   PubMed Web of Science ®Google Scholar
• Lindblad EB. 2004. Aluminium compounds for use in vaccines. Immunol Cell Biol. 82:497.
   PubMed Web of Science ®Google Scholar
• Liu CG, Liu M, Liu F, Liu da DF, Zhang Y, Pan WQ, et al. 2011. Evaluation of several adjuvants in avian influenza vaccine to chickens and ducks. Virol J. 8:321.
   PubMed Web of Science ®Google Scholar
• Luke CJ, Subbarao K. 2006. Vaccines for pandemic influenza. Emerg Infect Dis. 12:66.
   PubMed Web of Science ®Google Scholar
• Masurel N, Ophof P, De Jong P. 1981. Antibody response to immunization with influenza A/USSR/77 (H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus. J Hygiene. 87:201–209.
   PubMedGoogle Scholar
• Mishra N, Khatri K, Gupta M, Vyas SP. 2014. Development and characterization of LTA-appended chitosan nanoparticles for mucosal immunization against hepatitis B. Artif Cells Nanomed Biotechnol. 42:245–255.
   PubMed Web of Science ®Google Scholar
• Perez-Rebelo R. 1962. Immunity study of a new diluted formalin-inactivated Newcastle disease vaccine. Avian Dis. 6:284–289.
   Web of Science ®Google Scholar
• Pour M, Momayez R, Akhavizadegan M. 2006. The efficacy of inactivated oil-emulsion H9N2 avian influenza vaccine. Iran J Vet Res. 7:85–88.
   Google Scholar
• Reid GG, Blackall PJ. 1987. Comparison of adjuvants for an inactivated infectious coryza vaccine. Avian Dis. 31:59–63.
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Baars M, Claas EC, Osterhaus AD. 1998. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods. 74:57–66.
   PubMed Web of Science ®Google Scholar
• Stewart-Tull DE. 2000. Harmful and beneficial activities of immunological adjuvants. In: O'Hagan DT, Ed. Vaccine Adjuvants, vol. 42. New York: Springer, pp. 29–48.
   Google Scholar
• Stils HF Jr. 2005. Adjuvants and antibody production: dispelling the myths associated with Freund’s complete and other adjuvants. ILAR J. 46:280–293.
   PubMed Web of Science ®Google Scholar
• Stone H, Brugh M, Erickson G, Beard C. 1980. Evaluation of inactivated Newcastle disease oil-emulsion vaccines. Avian Dis. 24:99–111.
   Web of Science ®Google Scholar
• Vasievich EA, Huang L. 2011. The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharma. 8:635–641.
   PubMed Web of Science ®Google Scholar
• Vogel FR, Powell MF, Alving CR. 1995. A compendium of vaccine adjuvants and excipients. Vaccine Design: Subunit Adjuvant Approach. 6:141–228.
   Google Scholar
• Yamanaka M, Okabe T, Nakai M, Goto N. 1993. Local pathological reactions and immune response of chickens to ISA-70 and other adjuvants containing Newcastle disease virus antigen. Avian Dis. 73:459–466.
   Web of Science ®Google Scholar